Company intelligence / Profile preview

Mirus Bio

Madison, Wisconsin, United Statesmirusbio.com ↗

Ownership: Private
Development stage: Commercial

Overview

Mirus Bio does not develop therapeutics but provides industry-leading transfection reagents and nucleic acid delivery platforms that have been cited in over 10,000 peer-reviewed publications. Their products enable efficient production of viral vectors used in cell and gene therapy manufacturing workflows at both clinical and commercial scales. The company’s technology has supported advances in gene editing, protein production, RNA interference studies, genome engineering with CRISPR/Cas9 systems, among others.

Therapeutic areas: Other
Modalities: Nucleic acid delivery systemTransfection reagentElectroporation solutionNanoparticle-based delivery systemSmall interfering RNA (siRNA) toolPlasmid DNA transfection reagent
Industry: Non-Drug Biotech

Partnerships

Gamma Biosciences / KKR (prior owner)

Beyond the preview

Go deeper on Mirus Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mirus Bio.

Explore the full profile